Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Medtronic
Mallinckrodt
Harvard Business School
Dow

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,005,761

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,005,761
Title:Compounds and compositions as protein kinase inhibitors
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
Inventor(s): Huang; Shenlin (San Diego, CA), Jin; Xianming (San Ramon, CA), Liu; Zuosheng (San Diego, CA), Poon; Daniel (Piedmont, CA), Tellew; John (La Jolla, CA), Wan; Yongqin (Irvine, CA), Wang; Xing (San Diego, CA), Xie; Yongping (San Diego, CA)
Assignee: Array BioPharma Inc. (Boulder, CO)
Application Number:15/070,905
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 10,005,761

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-001 Jun 27, 2018 DISCN Yes No   Start Trial   Start Trial TREATMENT OF MELANOMA   Start Trial
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes   Start Trial   Start Trial TREATMENT OF MELANOMA   Start Trial
Array Biopharma Inc MEKTOVI binimetinib TABLET;ORAL 210498-001 Jun 27, 2018 RX Yes Yes   Start Trial   Start Trial INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,005,761

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 077975   Start Trial
Australia 2010286569   Start Trial
Canada 2771775   Start Trial
China 102725283   Start Trial
China 103896921   Start Trial
Colombia 6612222   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Merck
AstraZeneca
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.